The World Health Organization (WHO) has released updated guidelines calling for universal antiretroviral therapy for everyone diagnosed with HIV, regardless of CD4 T-cell count, and pre-exposure prophylaxis (PrEP) for people at substantial risk of infection. The organization estimates that the recommendations, if widely adopted, could avert 21 million deaths and prevent 28 million new infections worldwide by 2030.
Researchers presented findings from several HIV studies at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, including an overview of the START treatment initiation study, an all-women antiretroviral therapy trial, and studies of a better tolerated version of tenofovir (tenofovir alafenamide or TAF) and the experimental integrase inhibitor cabotegravir.
Newly diagnosed HIV infections and deaths among people living with HIV in San Francisco reached new lows in 2014, and the city continues to do a better job helping people get people tested and treated than the nation as a whole. But some notable disparities persist with regard to race, age, gender identity, and homelessness, according to the SF Department of Public Health's latest HIV Epidemiology Annual Report.
HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.
Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.